Pacific Biosciences of California Inc. Stock
Pacific Biosciences of California Inc. dominated the market today, gaining €0.12 (6.000%).
Currently there is a rather positive sentiment for Pacific Biosciences of California Inc. with 10 Buy predictions and 5 Sell predictions.
With a target price of 10 € there is potential for a 394.8% increase which would mean more than doubling the current price of 2.02 € for Pacific Biosciences of California Inc..
Our community identified positive and negative aspects for Pacific Biosciences of California Inc. stock for the coming years. 1 users see the criterium "Worthwhile Investment for the next years" as a plus for the Pacific Biosciences of California Inc. stock. On the other hand our users think that "Worthwhile Investment for the next years" could be a problem in the future.
Pros and Cons of Pacific Biosciences of California Inc. in the next few years
Pros
?
G***** c******* t* c**********
?
C******** o* t** e**********
?
M***** P*******
Cons
?
B****
?
S********** s********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Pacific Biosciences of California Inc. vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Pacific Biosciences of California Inc. | 6.000% | 26.456% | -26.117% | -82.799% | -78.951% | -89.850% | -69.636% |
MicroVision Inc | -3.870% | -22.648% | -17.919% | -55.405% | -53.966% | -89.925% | 58.177% |
Fonar Corp. New | -3.310% | -7.407% | -6.250% | -1.961% | -15.254% | -5.063% | -19.207% |
Allscripts Healthcare | - | -1.370% | -2.703% | -32.075% | -22.162% | -47.059% | -19.795% |
Comments
Pacific Biosciences of California, Inc. (NASDAQ: PACB) had its price target lowered by analysts at Sanford C. Bernstein from $9.00 to $2.50. They now have an "outperform" rating on the stock.
Show more
Ratings data for PACB provided by MarketBeat
Pacific Biosciences of California, Inc. (NASDAQ: PACB) was upgraded by analysts at StockNews.com to a "sell" rating.
Show more
Ratings data for PACB provided by MarketBeat
Pacific Biosciences of California, Inc. (NASDAQ: PACB) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $9.00 to $7.00. They now have a "buy" rating on the stock.
Show more
Ratings data for PACB provided by MarketBeat